Smallpox was one of the deadliest diseases in human history, killing an estimated 300 million people in the twentieth century alone before becoming the first and, so far, only human disease to be deliberately wiped off the planet. The World Health Organization certified its eradication in 1980, roughly two centuries after Edward Jenner demonstrated that cowpox material could protect against it. The story of how humanity went from helpless victim to victor involves ancient inoculation practices, Cold War diplomacy, a clever shift in public-health strategy, and a freeze-dried vaccine stable enough to survive tropical heat.
Where the Virus Came From
Variola virus, the pathogen behind smallpox, belongs to the orthopoxvirus family and infected only humans, with no animal reservoir to hide in. Exactly when it first jumped into people remains contentious. One phylogenetic analysis suggests two main viral lineages diverged from an ancestral African rodent-borne virus roughly 16,000 or 68,000 years ago, depending on which historical calibration point is used.1PubMed Central. On the origin of smallpox: correlating variola phylogenics with historical smallpox records A separate analysis of viral genomes and the geographic ranges of related orthopoxviruses places the emergence of variola more recently, around 3,000 to 4,000 years ago in eastern Africa, possibly triggered by the introduction of camels and shifts in climate that pushed an ancestral cowpox-like virus down a new evolutionary path.2PubMed Central. The origin of the variola virus
Ancient DNA has complicated things further. Researchers recovered variola DNA from Viking-era remains across northern Europe and dated the most recent common ancestor of known strains to roughly 1,700 years ago, which is far more recent than either of the older estimates.3PubMed. Diverse variola virus (smallpox) strains were widespread in northern Europe in the Viking Age That does not necessarily mean the virus did not exist before then; it may mean earlier lineages went extinct and the strains that eventually caused the epidemics we know descended from a more recent bottleneck. The disagreement among dating methods is a reminder that reconstructing the deep history of a virus whose last natural host died in 1977 is genuinely difficult.
What Smallpox Did to the Body and to Civilizations
The disease existed in two clinical forms. Variola major, sometimes called Asian smallpox, carried a fatality rate of roughly 20 to 45 percent. A milder variant known as variola minor, or alastrim, killed about 1 to 2 percent of those it infected and appeared in Europe and the Americas only toward the end of the nineteenth century.4PubMed. Life and death of smallpox Survivors of either form were often left with deep, pitted scars and sometimes blindness. Because variola major was so lethal and so disfiguring, it shaped population dynamics wherever it spread.
Perhaps nowhere was this devastation more acute than in the Americas after European contact. Indigenous populations had no prior exposure and therefore no inherited immune familiarity with orthopoxviruses. Smallpox, along with measles and other imported infections, tore through communities with extraordinary speed and lethality. The arrival of smallpox and the decline of Native American populations are, as one review puts it, inexorably linked.5PubMed. Smallpox and the Native American Entire societies collapsed not because of military defeat alone but because disease had already hollowed them out. Estimates of the population loss vary widely, but most historians agree that infectious disease, smallpox chief among them, was the single largest driver of demographic catastrophe in the post-contact New World.
Variolation and the Gamble of Early Prevention
Long before anyone understood viruses, people in several parts of the world noticed that surviving smallpox conferred lifelong protection. That observation led to variolation: deliberately introducing infectious material from a smallpox pustule into a healthy person’s skin, hoping to provoke a mild case. The practice was widespread in China, the Ottoman Empire, and parts of Africa well before it reached Britain and the American colonies in the early eighteenth century.6PubMed Central. The origins of inoculation
Variolation worked, but it was a calculated risk. The inoculated person received a live, fully virulent virus. Most developed a mild illness and recovered with immunity, yet the procedure carried a mortality rate of roughly 1 to 2 percent, and recipients could spread natural smallpox to others during their illness.6PubMed Central. The origins of inoculation When the alternative was a disease that killed one in three or more of its victims, those odds looked attractive. But variolation could itself spark outbreaks, which meant it was never going to be a tool for eradication. What the world needed was something that conferred immunity without the risk of full-blown disease.
Jenner’s Experiment and the Birth of Vaccination
That something arrived in 1796. Edward Jenner, a country physician in Gloucestershire, England, had long heard the folk wisdom that milkmaids who caught cowpox, a mild disease of cattle, seemed immune to smallpox. In May of that year, he took material from fresh cowpox lesions on the hand of a young dairymaid named Sarah Nelmes and inoculated it into the arm of eight-year-old James Phipps, the son of his gardener. Phipps developed a brief, mild illness. When Jenner later attempted to expose the boy to smallpox, nothing happened.7PubMed Central. Edward Jenner and the history of smallpox and vaccination
Jenner’s insight was that a related but far less dangerous virus could train the immune system to recognize and fight variola. The word “vaccination” itself comes from vacca, Latin for cow. His technique spread across Europe within a few years and was eventually mandated by law in several countries during the nineteenth century. It was not without controversy: anti-vaccination sentiment is nearly as old as vaccination itself, driven by mistrust of authority and by the occasional real complication. But the principle held, and over the following century vaccination gradually replaced variolation everywhere it was introduced.
The Freeze-Dried Breakthrough
For more than 150 years after Jenner, the biggest obstacle to global vaccination was logistics. Traditional liquid smallpox vaccine lost potency quickly in warm climates, which meant it was almost useless across large stretches of the tropics where smallpox remained entrenched. The development of freeze-dried (lyophilized) vaccine in the mid-twentieth century changed the equation. Studies showed that when the residual moisture content of freeze-dried vaccine was kept below about 1 percent, the vaccine remained potent even at elevated temperatures.8PubMed Central. The effect of residual moisture in lyophilized smallpox vaccine on its stability at different temperatures At refrigerator temperature, vaccine with moisture content of nearly 5 percent held up well, and even at tropical room temperature, vaccine stayed stable if moisture was kept under about 2.5 percent.8PubMed Central. The effect of residual moisture in lyophilized smallpox vaccine on its stability at different temperatures
This seemingly dry technical detail was transformative. It meant vaccine could be shipped to remote clinics in sub-Saharan Africa, South Asia, and South America and still work when it got there. Paired with the bifurcated needle, a simple two-pronged tool that picked up just the right amount of vaccine in its fork, freeze-dried vaccine made mass immunization campaigns in low-resource settings feasible for the first time.
Cold War Diplomacy and the WHO Campaign
Global eradication was not inevitable; it required political will at the highest level. In 1958, the Soviet Union proposed a worldwide smallpox eradication effort to the World Health Assembly. The resolution passed, but early progress was slow and uneven. A closer look at the diplomatic record reveals that the campaign was the product of intense negotiation among member states, and historians have challenged the long-standing assumption that the fight against smallpox only gained real momentum after the mid-1960s, when a U.S.-backed program in West Africa and a reinvigorated WHO effort got underway.9PubMed Central. Re-assessing the Foundations: Worldwide Smallpox Eradication, 1957-67
In 1966 the WHO launched its Intensified Smallpox Eradication Programme, eventually led by the American epidemiologist D.A. Henderson. The programme’s initial strategy was mass vaccination: vaccinate enough people and the virus would run out of hosts. In wealthy countries with strong health infrastructure, that approach had already worked. But in the countries where smallpox persisted, mass vaccination alone was proving insufficient.
The Shift to Surveillance and Containment
The turning point came from field experience in West Africa, later confirmed by data from Indonesia and South Asia. Epidemiologists noticed that smallpox did not actually spread as fast as many assumed. An infected person could transmit the virus, but the disease moved through communities slowly enough that outbreaks could be snuffed out if you found every case quickly, isolated patients, and vaccinated everyone around them.10PubMed Central. Mass vaccination and surveillance/containment in the eradication of smallpox This approach, known as surveillance and containment (or ring vaccination), redirected resources away from trying to vaccinate entire populations and toward finding and encircling every last outbreak.
In practice, it meant enormous legwork. Health workers conducted house-to-house searches across vast rural areas. Governments offered rewards to anyone who reported a case. When a case was found, the patient was isolated and every contact was vaccinated and monitored.11American Journal of Infection Control. The global eradication of smallpox The strategy exploited a key biological weakness of variola: it had no animal host to retreat into. Every chain of transmission ran through humans, and if you could break every chain, the virus had nowhere to go. The shift to surveillance and containment accelerated the program’s progress dramatically.10PubMed Central. Mass vaccination and surveillance/containment in the eradication of smallpox
The Last Natural Case
By the mid-1970s, smallpox had been cornered in the Horn of Africa. On October 26, 1977, a Somali hospital cook and health worker named Ali Maow Maalin developed a rash that was confirmed as variola minor. He survived, and his case turned out to be the last known instance of naturally acquired smallpox on Earth.12AAP News. What is Ali Maalin’s claim to fame? Maalin later became a polio-vaccination campaigner in Somalia, dedicating his career to the kind of public-health effort that had ended the disease he once suffered from.
There was one tragic postscript. In 1978, a medical photographer named Janet Parker at the University of Birmingham in England contracted smallpox from a laboratory specimen and died. Her death prompted tighter controls on variola stocks worldwide and underscored the risk that the virus could escape even in a post-eradication world. After two years of global surveillance with no further natural cases, the World Health Assembly declared smallpox officially eradicated on May 8, 1980.
Why Variola Virus Still Exists in Laboratories
Eradication from nature did not mean eradication from the planet. Two laboratories, the Centers for Disease Control and Prevention in Atlanta and the VECTOR research center in Novosibirsk, Russia, were authorized to retain live variola stocks. The debate over whether to destroy those remaining samples has simmered for decades. Proponents of destruction argue that keeping the virus alive creates a perpetual biosecurity risk. Opponents counter that the stocks are needed for ongoing research into diagnostics, vaccines, and treatments, and that synthetic biology could theoretically reconstruct the genome anyway.
Fears about deliberate misuse have real historical grounding. In 1971, a smallpox outbreak struck the Soviet city of Aralsk, Kazakhstan, linked to field testing of a weaponized variola strain on a nearby island in the Aral Sea.13PubMed. The 1971 smallpox outbreak in the Soviet city of Aralsk The Soviet biological weapons program had pursued smallpox as an offensive agent for years. That history is part of the reason the U.S. government classifies variola as a Category A bioterrorism threat and has invested heavily in countermeasures even though the disease no longer circulates naturally.
Modern Countermeasures Against a Vanquished Disease
If smallpox no longer exists in the wild, why does anyone still develop drugs and vaccines against it? The answer is preparedness. In July 2018, the U.S. Food and Drug Administration approved tecovirimat (brand name TPOXX), the first antiviral specifically indicated for the treatment of symptomatic smallpox.14PubMed Central. An overview of tecovirimat for smallpox treatment and expanded anti-orthopoxvirus applications The drug works by blocking a protein that the virus needs to release new viral particles from infected cells. It was developed with government funding and stockpiled as part of the Strategic National Stockpile, meaning it sits in reserve should the unthinkable happen.15PubMed Central. The development and approval of tecoviromat (TPOXX), the first antiviral against smallpox
Newer-generation vaccines have also been developed. JYNNEOS (also called Imvanex or Imvamune depending on the country) is a non-replicating vaccinia-based vaccine that was licensed for both smallpox and mpox prevention. Unlike the original vaccinia vaccine, it does not produce a spreading skin lesion and is considered safer for people with weakened immune systems. These tools exist less because anyone expects variola to reappear spontaneously and more because governments want options in case of accidental release or deliberate attack.
Waning Immunity and the Rise of Mpox
Routine smallpox vaccination ended worldwide by the early 1980s. That means anyone born after about 1980, which is now the majority of the global population, has never been vaccinated. Even among those who were vaccinated decades ago, immunity has faded considerably. Modeling of New York City and Sydney, for instance, found that residual vaccine immunity is now so low that population-level immunosuppression, affecting at least 17 to 19 percent of those cities’ residents, has a bigger influence on projected smallpox outbreak severity than leftover vaccination does.16PubMed Central. Influence of Population Immunosuppression and Past Vaccination on Smallpox Reemergence
The practical consequence of this immunity gap is already visible, not through smallpox itself but through mpox. Mpox virus is a close relative of variola, and smallpox vaccination provided substantial cross-protection against it. With that protection gone from most of the population, mpox has increasingly been able to sustain human-to-human transmission. Waning population immunity after the end of routine smallpox vaccination plays a key role in the changing patterns of mpox outbreaks, and sustained human-to-human transmission is now occurring widely enough to fuel genetic mutations in the virus.17PubMed Central. The Rise of Mpox in a Post-Smallpox World
The geographic distribution of remaining vaccination coverage is strikingly uneven. A global mapping study found that regional vaccination levels range from about 7 percent to 60 percent, with the highest coverage in parts of Finland, Bulgaria, Japan, and Sweden, and the lowest in Yemen, Colombia, Guinea-Bissau, and Ethiopia. Central and western Africa, where mpox spillover from animal reservoirs is most common, had particularly low levels of residual protection.18The Lancet Infectious Diseases. Global landscape of smallpox vaccination and orthopoxvirus susceptibility The irony is hard to miss: the very success of smallpox eradication removed the incentive for vaccination that once kept a whole family of related viruses in check.
Poxvirus DNA in Historical Remains
One lesser-known thread in the smallpox story involves archaeology. Researchers have recovered poxvirus DNA from mummified remains, old scabs preserved in medical collections, and other historical relics. These specimens have provided valuable genetic data for reconstructing the virus’s evolutionary history, but they also raise biosecurity questions. Although intact, viable variola virus has not been recovered from ancient remains, each discovery prompts careful evaluation because the theoretical risk cannot be dismissed outright.19PubMed Central. Poxvirus viability and signatures in historical relics The Viking-era variola genomes mentioned earlier, for example, revealed that smallpox strains circulating over a thousand years ago were genetically distinct from the strains that caused the major epidemics of recent centuries, hinting at viral lineages that went extinct without leaving modern descendants.3PubMed. Diverse variola virus (smallpox) strains were widespread in northern Europe in the Viking Age
These findings are more than academic curiosities. They help scientists understand how orthopoxviruses evolve, how quickly they can change, and what conditions favor new variants. In a world where mpox is spreading more aggressively and where synthetic biology could theoretically reconstruct dangerous pathogens, that evolutionary knowledge has practical biosecurity value. The history of smallpox did not end in 1980. It just shifted from hospitals and vaccination lines to freezers, genome databases, and the quiet planning rooms where governments prepare for threats they hope will never materialize.